Literature DB >> 21378572

The role of PET/computed tomography scan in the management of prostate cancer.

Maria Picchio1, Elisabetta Giovannini, Cristina Messa.   

Abstract

PURPOSE OF REVIEW: To evaluate the role of PET/computed tomography (CT) imaging in patients with prostate cancer and to provide clinical recommendations, both in pretreatment and in post-treatment phase. RECENT
FINDINGS: The potential role of PET/CT for evaluating intraprostatic disease, staging and restaging prostate cancer patients has been largely investigated. In particular, among the different PET tracers evaluated, choline, acetate and fluoride are showing the most promising results for imaging prostate cancer and its metastases. However, although choline PET/CT is an established diagnostic tool for imaging prostate cancer patients, as documented by a large amount of literature, further studies are still necessary to establish the final clinical role of PET/CT with acetate and fluoride.
SUMMARY: Choline PET/CT is clinically indicated to noninvasively restage, in one single session, prostate cancer patients presenting a progressive increase of prostate-specific antigen, after radical treatment. Conversely, choline PET/CT does not allow the accurate assessment of intraprostatic tumor and of small lymph nodal involvement, thus not being currently recommended as a first-line method for initial diagnosis and staging. The current use of PET/CT with acetate and fluoride in clinical practice still needs further confirmations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378572     DOI: 10.1097/MOU.0b013e328344e556

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  9 in total

Review 1.  Unmet needs in the prediction and detection of metastases in prostate cancer.

Authors:  Oliver Sartor; Mario Eisenberger; Michael W Kattan; Bertrand Tombal; Frederic Lecouvet
Journal:  Oncologist       Date:  2013-05-06

2.  PET/CT imaging and the oligometastatic prostate cancer patient: an opportunity for a curative approach with high-dose radiotherapy?

Authors:  Raymond Miralbell; Franz Buchegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07       Impact factor: 9.236

Review 3.  Prognostic Utility of PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2015-01-22

Review 4.  F18-choline/C11-choline PET/CT thyroid incidentalomas.

Authors:  Francesco Bertagna; Domenico Albano; Luca Giovanella; Raffaele Giubbini; Giorgio Treglia
Journal:  Endocrine       Date:  2019-01-12       Impact factor: 3.633

Review 5.  Multidisciplinary management of Prostate Cancer: how and why.

Authors:  Alessandro Sciarra; Vincenzo Gentile; Valeria Panebianco
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

Review 6.  Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.

Authors:  Andrei H Iagaru; Erik Mittra; Patrick M Colletti; Hossein Jadvar
Journal:  J Nucl Med       Date:  2016-10       Impact factor: 10.057

7.  ¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy.

Authors:  Daniel C Bortot; Bárbara J Amorim; Glaucia C Oki; Sérgio B Gapski; Allan O Santos; Mariana C L Lima; Elba C S C Etchebehere; Marycel F Barboza; Jair Mengatti; Celso Dario Ramos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-04       Impact factor: 9.236

Review 8.  Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview.

Authors:  Sergey Reva; Alexander Nosov; Roman Novikov; Sergey Petrov
Journal:  Int Sch Res Notices       Date:  2014-07-15

9.  3 Tesla multiparametric MRI for GTV-definition of Dominant Intraprostatic Lesions in patients with Prostate Cancer--an interobserver variability study.

Authors:  Hans Christian Rischke; Ursula Nestle; Tobias Fechter; Christian Doll; Natalja Volegova-Neher; Karl Henne; Jutta Scholber; Stefan Knippen; Simon Kirste; Anca L Grosu; Cordula A Jilg
Journal:  Radiat Oncol       Date:  2013-07-22       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.